BR112021008200A2 - Composições e métodos para distúrbios de alfa-1-antitripsina - Google Patents
Composições e métodos para distúrbios de alfa-1-antitripsinaInfo
- Publication number
- BR112021008200A2 BR112021008200A2 BR112021008200A BR112021008200A BR112021008200A2 BR 112021008200 A2 BR112021008200 A2 BR 112021008200A2 BR 112021008200 A BR112021008200 A BR 112021008200A BR 112021008200 A BR112021008200 A BR 112021008200A BR 112021008200 A2 BR112021008200 A2 BR 112021008200A2
- Authority
- BR
- Brazil
- Prior art keywords
- alpha
- compositions
- antitrypsin
- methods
- disorders
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title abstract 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title abstract 2
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title abstract 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752182P | 2018-10-29 | 2018-10-29 | |
| PCT/US2019/058673 WO2020092448A1 (en) | 2018-10-29 | 2019-10-29 | Compositions and methods for alpha-1-antitrypsin disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021008200A2 true BR112021008200A2 (pt) | 2021-12-14 |
Family
ID=68771752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021008200A BR112021008200A2 (pt) | 2018-10-29 | 2019-10-29 | Composições e métodos para distúrbios de alfa-1-antitripsina |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12497441B2 (https=) |
| EP (1) | EP3873926A1 (https=) |
| JP (2) | JP7731288B2 (https=) |
| KR (1) | KR20210111245A (https=) |
| CN (1) | CN113286816B (https=) |
| AU (1) | AU2019369403B2 (https=) |
| BR (1) | BR112021008200A2 (https=) |
| CA (1) | CA3117961A1 (https=) |
| WO (1) | WO2020092448A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200385713A1 (en) | 2019-01-22 | 2020-12-10 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| CA3127243A1 (en) | 2019-01-22 | 2020-07-30 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| EP3914260A4 (en) | 2019-01-22 | 2023-05-17 | Korro Bio, Inc. | RNA-EDITING OLIGONUCLEOTIDES AND THEIR USE |
| KR20230033651A (ko) * | 2020-05-28 | 2023-03-08 | 코로 바이오, 인크. | Serpina1의 adar-매개 편집을 위한 방법 및 조성물 |
| AU2021375735A1 (en) * | 2020-11-06 | 2023-06-08 | Aatec Medical Gmbh | A composition comprising extra-cellular vesicles from mesenchymal stem cells and alpha-1 antitrypsin for the treatment of viral infections |
| US20240101630A1 (en) * | 2020-12-18 | 2024-03-28 | Cullinan Amber Corp. | Bi-functional linear fusion collagen-localized immunomodulatory molecules and methods thereof |
| CN117942275A (zh) * | 2022-10-31 | 2024-04-30 | 康码（上海）生物科技有限公司 | 一种基于病毒阻断剂的洗手液及其应用 |
| CN121100127A (zh) * | 2023-05-05 | 2025-12-09 | 保罗·托马斯·金 | 新型治疗性多肽 |
| EP4730999A1 (en) * | 2023-06-22 | 2026-04-29 | AATEC Medical GmbH | Recombinant aat from yeast to treat transplants |
| EP4480493A1 (en) | 2023-06-22 | 2024-12-25 | AATEC Medical GmbH | A recombinant human alpha-1 antitrypsin glycoprotein for treating non-viral inflammatory diseases of the lung |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| GB8909916D0 (en) * | 1989-04-29 | 1989-06-14 | Delta Biotechnology Ltd | Polypeptides |
| GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
| US6632637B1 (en) | 1999-10-13 | 2003-10-14 | Immunex Corporation | Vectors and methods for recombinant protein expression |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2003066824A2 (en) | 2002-02-07 | 2003-08-14 | Aventis Behring Gmbh | Albumin-fused kunitz domain peptides |
| EP2287326A1 (en) | 2003-08-08 | 2011-02-23 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
| US20070269442A1 (en) | 2006-05-19 | 2007-11-22 | Robert J. Webber | Chimeric monoclonal antibody recognizing iNOS |
| AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| WO2008086524A2 (en) | 2007-01-11 | 2008-07-17 | University Of Florida Research Foundation, Inc. | Alpha-1-antitrypsin variants and uses thereof |
| KR100992526B1 (ko) | 2007-11-21 | 2010-11-05 | 한국과학기술연구원 | 이황화결합을 이용한 내열성의 알파-1-안티트립신 뮤테인및 그의 제조방법 |
| US8341615B2 (en) | 2008-07-11 | 2012-12-25 | International Business Machines Corporation | Single instruction multiple data (SIMD) code generation for parallel loops using versioning and scheduling |
| JP5727459B2 (ja) | 2009-04-22 | 2015-06-03 | アルテオゼン， インクＡｌｔｅｏｇｅｎ， Ｉｎｃ | 体内持続性を維持することにより体内半減期が増加したタンパク質またはペプチド融合体 |
| AU2012275295B2 (en) * | 2011-06-28 | 2016-11-10 | Inhibrx, Lp | WAP domain fusion polypeptides and methods of use thereof |
| KR102231139B1 (ko) | 2011-06-28 | 2021-03-24 | 인히브릭스, 인크. | 세르핀 융합 폴리펩타이드 및 이의 이용 방법 |
| US10400029B2 (en) * | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| CA2896951A1 (en) * | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| GB201322091D0 (en) * | 2013-12-13 | 2014-01-29 | Cambridge Entpr Ltd | Modified serpins for the treatment of bleeding disorders |
| NZ769391A (en) * | 2014-10-27 | 2024-12-20 | Sanofi Aatd Inc | Serpin fusion polypeptides and methods of use thereof |
| EP3600345A4 (en) | 2017-03-29 | 2021-01-06 | Cornell University | OXIDATION-RESISTANT AAT GENE THERAPY |
| CN110092828B (zh) | 2018-01-31 | 2021-08-24 | 北京大学 | 重组突变体α1-抗胰蛋白酶及其制备和应用 |
-
2019
- 2019-10-29 CA CA3117961A patent/CA3117961A1/en active Pending
- 2019-10-29 CN CN201980084112.0A patent/CN113286816B/zh active Active
- 2019-10-29 WO PCT/US2019/058673 patent/WO2020092448A1/en not_active Ceased
- 2019-10-29 US US17/289,136 patent/US12497441B2/en active Active
- 2019-10-29 BR BR112021008200A patent/BR112021008200A2/pt unknown
- 2019-10-29 EP EP19813978.4A patent/EP3873926A1/en active Pending
- 2019-10-29 AU AU2019369403A patent/AU2019369403B2/en active Active
- 2019-10-29 JP JP2021548539A patent/JP7731288B2/ja active Active
- 2019-10-29 KR KR1020217016440A patent/KR20210111245A/ko not_active Ceased
-
2024
- 2024-06-26 JP JP2024103143A patent/JP2024123234A/ja active Pending
-
2025
- 2025-11-13 US US19/388,528 patent/US20260092099A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210388059A1 (en) | 2021-12-16 |
| US20260092099A1 (en) | 2026-04-02 |
| CN113286816A (zh) | 2021-08-20 |
| WO2020092448A1 (en) | 2020-05-07 |
| KR20210111245A (ko) | 2021-09-10 |
| AU2019369403B2 (en) | 2025-04-17 |
| AU2019369403A1 (en) | 2021-05-20 |
| US12497441B2 (en) | 2025-12-16 |
| JP7731288B2 (ja) | 2025-08-29 |
| JP2024123234A (ja) | 2024-09-10 |
| JP2022509517A (ja) | 2022-01-20 |
| EP3873926A1 (en) | 2021-09-08 |
| CN113286816B (zh) | 2025-04-04 |
| CA3117961A1 (en) | 2020-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021008200A2 (pt) | Composições e métodos para distúrbios de alfa-1-antitripsina | |
| CY1125136T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1124013T1 (el) | Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη | |
| CY1123381T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| CY1122148T1 (el) | Συνθεσεις που περιεχουν βακτηριακα στελεχη | |
| JOP20200228A1 (ar) | تركيبات وطرق لخفض تعبير البروتين tau | |
| CY1122184T1 (el) | Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη | |
| BR112018075833A2 (pt) | composições compreendendo cepas bacterianas | |
| MX379270B (es) | Composiciones que comprenden cepas bacterianas. | |
| BR112019006160A2 (pt) | composições e métodos para o tratamento das condições oftálmicas | |
| EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
| MX377141B (es) | Composiciones y metodos para modular la expresion de pkk. | |
| BR112016008541A2 (pt) | composições úteis para tratar distúrbios relacionados a kit | |
| BR112016000654A2 (pt) | composições para a modulação de expressão de tau | |
| MX389449B (es) | Composiciones de inh-c1 y métodos para la prevención y el tratamiento de trastornos asociados con la deficiencia del inhibidor de c1 esterasa. | |
| EA202091731A1 (ru) | Ингибиторы аутотаксина и их применения | |
| EA202191471A1 (ru) | Противовоспалительные полипептиды | |
| MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
| CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
| CL2022000967A1 (es) | Composiciones y métodos para el tratamiento de enfermedades hepáticas | |
| MX2020012990A (es) | Formulaciones de tegavivint y compuestos relacionados. | |
| MX2019010060A (es) | Composiciones y metodo para tratar cancer. | |
| BR112021019448A2 (pt) | Métodos para o tratamento de beta-talassemia | |
| MX2017013729A (es) | Deteccion especifica de isoformas de clusterina. | |
| BR112022000374A2 (pt) | Composições microbianas |